Rifadin IV (RIFAMPIN)
Rifadin IV (RIFAMPIN) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Rifadin IV; Generic name: RIFAMPIN; Drug class: Rifamycin Antibacterial [EPC].
| Brand name | Rifadin IV |
|---|---|
| Generic name | RIFAMPIN |
| Drug class | Rifamycin Antibacterial [EPC] |
| Manufacturer | Sanofi-Aventis U.S. LLC |
| Used for | INDICATIONS AND USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regim |
| Dosage | DOSAGE AND ADMINISTRATION Rifampin can be administered by the oral route or by IV infusion (see INDICATIONS AND USAGE ). IV doses are the same as those for oral. See CLINICAL PHARMACOLOGY for dosing information in patients with renal failure. Tuberculosis Adults: 10 mg/kg, in a single daily administration, not to exceed 600 mg/day, oral or IV Pediatric Patients: 10–20 mg/kg, not to exceed 600 mg/day, oral or IV It is recommended that oral rifampin be administered once daily, either 1 hour before |
| Warnings | WARNINGS Hepatotoxicity of hepatocellular, cholestatic, and mixed patterns has been reported in patients treated with rifampin. Severity ranged from asymptomatic elevations in liver enzymes, isolated jaundice/hyperbilirubinemia, symptomatic self-limited hepatitis to fulminant liver failure and death. Severe hepatic dysfunction including fatalities were reported in patients with liver disease and in patients taking rifampin with other hepatotoxic agents. Monitor for symptoms and clinical/laborato |
| Active ingredient(s) | RIFAMPIN |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=036ab68e-5085-4edc-bd83-784b43d64eab |